Other safety alerts
|
| |
| The United Kingdom: Thiopurines and intrahepatic cholestasis of pregnancy |
| |
Medicines and Healthcare products Regulatory Agency (MHRA) announces that intrahepatic cholestasis of pregnancy (ICP) has been rarely reported in patients treated with azathioprine products, and is believed to be a risk applicable to all drugs in the thiopurine class (azathioprine, mercaptopurine and tioguanine). Cholestasis of pregnancy associated with thiopurines tends to occur earlier in pregnancy than non drug-induced cholestasis of pregnancy, and elevated bile acid levels may not reduce with ursodeoxycholic acid.
The thiopurines include azathioprine, mercaptopurine and thioguanine (also known as tioguanine). Their uses are in anticancer indications, primarily leukaemia, and immunosuppression to treat inflammatory disorders such as inflammatory bowel diseases (IBD) and to increase graft survival following organ transplant. Thiopurines should only be used in pregnancy where a careful benefit/risk assessment for the individual patient has been made.
A risk of developing intrahepatic cholestasis of pregnancy (ICP) has been identified from a small number of case reports in the scientific literature. ICP has been reported in some pregnant patients treated with azathioprine and mercaptopurine and, due to similar metabolic pathways utilised by thiopurines, this risk is believed to be applicable to all drugs in the thiopurine class (azathioprine, mercaptopurine and tioguanine).
For context, the occurrence of thiopurine-induced ICP is thought to occur much less frequently than non thiopurine-induced ICP, which occurs in roughly 1 in every 150 pregnancies.
Case reports occur mainly in patients being treated for IBD or in transplant recipients. In many cases, ICP associated with thiopurine treatment has developed earlier in pregnancy than typical non drug-induced ICP and in some cases bile acid levels did not reduce with ursodeoxycholic acid. However, in some cases, improvement in bile acid and liver function did occur on stopping thiopurine. Reported cases were often serious with some resulting in fetal death. However, reporting bias may result in the more serious cases being reported.
Advice for Healthcare Professionals:
• cholestasis of pregnancy has rarely been reported in association with azathioprine therapy
• this risk is believed to also apply to the other thiopurine drugs, mercaptopurine and tioguanine
• it may occur earlier in pregnancy than non drug-induced cholestasis of pregnancy, and it may not respond to ursodeoxycholic acid
• withdrawal or dose reduction of the thiopurine drug may improve liver function tests
• remain vigilant to signs and symptoms of ICP in pregnant patients taking thiopurines and discuss any concerns with clinicians managing the patient’s immunosuppressant therapy and a hepatologist, as necessary
• if cholestasis of pregnancy occurs, a case-by-case assessment is required to determine the appropriate course of action. Consider the risks and benefits of remaining on the product against the risks and benefits of stopping
• in patients with ICP, measure serum bile acids to identify pregnancies at particular risk of spontaneous preterm birth (≥40uM) or stillbirth (non-fasting serum bile acids ≥100uM)
Please refer to the following website in MHRA for details:
http://www.gov.uk/drug-safety-update/thiopurines-and-intrahepatic-cholestasis-of-pregnancy
In Hong Kong, there are registered pharmaceutical products containing azathioprine (8 products), mercaptopurine (2 products) and tioguanine (2 products). All products are prescription-only medicines. So far, the Department of Health (DH) has received adverse drug reaction with regard to azathioprine (21 cases), mercaptopurine (15 cases) and tioguanine (4 cases), but these cases were not related to intrahepatic cholestasis of pregnancy (ICP).
The risk of intrahepatic cholestasis of pregnancy associated with the use of thiopurines is documented in overseas reputable drug references such as “The American Hospital Formulary Service (AHFS) Drug Information”. The DH will remain vigilant on any safety update of the drugs issued by other overseas drug regulatory authorities.
Ends/Friday, May 16, 2025
Issued at HKT 18:00
|
| |
